{"nctId":"NCT00276094","briefTitle":"A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women","startDateStruct":{"date":"2006-01"},"conditions":["Atrophy","Vaginal Diseases"],"count":826,"armGroups":[{"label":"Ospemifene 30 mg/day and nonhormonal vaginal lubricant","type":"EXPERIMENTAL","interventionNames":["Drug: Ospemifene 30 mg","Drug: Nonhormonal vaginal lubricant"]},{"label":"Ospemifene 60 mg/day and nonhormonal vaginal lubricant","type":"EXPERIMENTAL","interventionNames":["Drug: Ospemifene 60 mg","Drug: Nonhormonal vaginal lubricant"]},{"label":"Placebo tablets and nonhormonal vaginal lubricant","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Nonhormonal vaginal lubricant"]}],"interventions":[{"name":"Ospemifene 30 mg","otherNames":[]},{"name":"Ospemifene 60 mg","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Nonhormonal vaginal lubricant","otherNames":["K-YÂ® Brand Jelly"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Naturally or surgically postmenopausal\n* Moderate or severe symptoms of vaginal atrophy (ie, vaginal dryness, irritation or itching, difficult or painful urination, pain or bleeding with intercourse)\n* Vaginal pH greater than 5.0\n* 5% or fewer superficial cells in maturation index of vaginal smear\n\nExclusion Criteria:\n\n* Evidence of endometrial hyperplasia, endometrial cancer, or other abnormal endometrial pathology\n* Abnormal Pap smear\n* Uterine bleeding of unknown origin or uterine polyps\n* Current vaginal infection requiring medication","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"40 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change From Baseline in the Most Bothersome Vulvar and Vaginal Atrophy (VVA) Symptom (MBS) of Vaginal Dryness","description":"This outcome measure was analyzed using Cochran-Mantel-Haenszel (CMH) row mean scores test controlling for study center and uterine status. VVA Symptom Score: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.22","spread":"0.929"},{"groupId":"OG001","value":"-1.26","spread":"1.025"},{"groupId":"OG002","value":"-0.84","spread":"0.996"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline in the MBS of Vaginal Pain Associated With Sexual Activity","description":"This outcome measure was analyzed using CMH row mean scores test controlling for study center and uterine status. VVA Symptom Score: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.02","spread":"1.132"},{"groupId":"OG001","value":"-1.19","spread":"1.292"},{"groupId":"OG002","value":"-0.89","spread":"1.115"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline in Vaginal pH","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.67","spread":"1.054"},{"groupId":"OG001","value":"-1.01","spread":"1.053"},{"groupId":"OG002","value":"-0.096","spread":"0.8357"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline in Percentage of Parabasal Cells in Maturation Index of Vaginal Smear","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.9","spread":"32.60"},{"groupId":"OG001","value":"-30.1","spread":"37.93"},{"groupId":"OG002","value":"3.98","spread":"35.205"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Visual Evaluation of the Vagina","description":"Exam Rating Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.50","spread":"0.829"},{"groupId":"OG001","value":"-0.60","spread":"0.848"},{"groupId":"OG002","value":"-0.037","spread":"0.8080"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.75","spread":"0.914"},{"groupId":"OG001","value":"-0.93","spread":"0.930"},{"groupId":"OG002","value":"-0.30","spread":"0.940"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.57","spread":"0.922"},{"groupId":"OG001","value":"-0.71","spread":"0.911"},{"groupId":"OG002","value":"-0.16","spread":"0.818"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.05","spread":"0.959"},{"groupId":"OG001","value":"-1.22","spread":"0.981"},{"groupId":"OG002","value":"-0.48","spread":"0.911"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.44","spread":"0.811"},{"groupId":"OG001","value":"-0.60","spread":"0.924"},{"groupId":"OG002","value":"-0.23","spread":"0.792"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Severity of VVA Symptoms","description":"This outcome measure was analyzed using CMH row mean scores test controlling for study center and uterine status. VVA Symptom Score: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.96","spread":"1.018"},{"groupId":"OG001","value":"-1.17","spread":"1.050"},{"groupId":"OG002","value":"-0.63","spread":"1.047"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.77","spread":"1.200"},{"groupId":"OG001","value":"-0.87","spread":"1.278"},{"groupId":"OG002","value":"-0.57","spread":"1.224"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.40","spread":"1.080"},{"groupId":"OG001","value":"-0.58","spread":"0.982"},{"groupId":"OG002","value":"-0.44","spread":"0.948"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.17","spread":"0.676"},{"groupId":"OG001","value":"-0.20","spread":"0.673"},{"groupId":"OG002","value":"-0.097","spread":"0.6745"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.26","spread":"0.807"},{"groupId":"OG001","value":"-0.23","spread":"0.707"},{"groupId":"OG002","value":"-0.12","spread":"0.667"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Estradiol Levels","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.44","spread":"19.01"},{"groupId":"OG001","value":"1.02","spread":"12.74"},{"groupId":"OG002","value":"0.30","spread":"3.90"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline in the Percentage of Superficial Cells in Maturation Index of Vaginal Smear","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.78","spread":"12.136"},{"groupId":"OG001","value":"10.8","spread":"15.66"},{"groupId":"OG002","value":"2.18","spread":"8.393"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Follicle Stimulating Hormone Levels","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.93","spread":"12.49"},{"groupId":"OG001","value":"-8.71","spread":"13.61"},{"groupId":"OG002","value":"-1.33","spread":"10.87"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Luteinizing Hormone Levels","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.85","spread":"6.07"},{"groupId":"OG001","value":"-3.73","spread":"5.83"},{"groupId":"OG002","value":"0.41","spread":"7.25"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Sex Hormone Binding Globulin Levels","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":"16.46"},{"groupId":"OG001","value":"22.8","spread":"22.06"},{"groupId":"OG002","value":"-2.17","spread":"12.02"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Testosterone (Free) Levels","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.002","spread":"0.51"},{"groupId":"OG001","value":"-0.031","spread":"0.15"},{"groupId":"OG002","value":"-0.008","spread":"0.13"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Testosterone (Total) Levels","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.55","spread":"18.82"},{"groupId":"OG001","value":"1.92","spread":"5.56"},{"groupId":"OG002","value":"-0.059","spread":"6.07"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Urinary Symptoms","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"63","spread":null},{"groupId":"OG002","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"53","spread":null},{"groupId":"OG002","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"56","spread":null},{"groupId":"OG002","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"16","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":282},"commonTop":["Hot Flush","Urinary Tract Infection","Headache","Vaginal Discharge","Sinusitis"]}}}